Swedish pharmaceutical company Orexo AB (STO:ORX) (OTCQX:ORXOY) on Tuesday announced a collaboration with Abera Bioscience to develop nasal powder vaccines using Orexo's AmorphOX technology.
AmorphOX has the potential to improve the stability and efficacy of Abera's vaccine candidates, particularly for intranasal delivery.
The partnership aims to develop powder-based intranasal influenza vaccine candidates, leveraging Abera's innovative vaccine platform and Orexo's drug delivery technology.
The collaboration is funded by Abera through various grants, primarily from the Coalition for Epidemic Preparedness Innovation (CEPI).
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Alzinova AB reports positive final Phase 1b results for ALZ-101 in Alzheimer's
Primrose Bio launches Prima RNApols ExTend RNA polymerase for long-template mRNA manufacturing
Merck's CAPVAXIVE approved by EC for pneumococcal disease prevention
Sanofi secures FDA fast track designation for chlamydia vaccine candidate
Anixa Biosciences secures US patent allowance for ovarian cancer vaccine
Valneva to supply IXCHIQ vaccine for chikungunya outbreak in La Réunion
Everest Medicines' EVM14 IND application receives US FDA approval
Clover Biopharmaceuticals' SCB-1019 IND application receives US FDA approval
Centivax partners with Emery Pharma on universal flu vaccine
Avance Biosciences registers with CLIA program
GSK receives approval from US FDA for Penmenvy 5-in-1 meningitis vaccine
hVIVO secures GBP2m contract for final stage of hMPV characterisation study
EU approves CSL and Arcturus Therapeutics' self-amplifying mRNA COVID-19 vaccine